Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oragenics Inc OGEN

Healthcare Biotechnology
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for... see more

Recent & Breaking News (NYSEAM:OGEN)

Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

Business Wire January 26, 2022

Oragenics Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant

Business Wire December 20, 2021

Oragenics to Participate in Virtual Fireside Chat Hosted by Alliance Global Partners

Business Wire December 9, 2021

Oragenics Co-Authors a Publication Describing the Dual Mechanism of Action of Lantibiotics

Business Wire December 8, 2021

Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate

Business Wire December 1, 2021

Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

Business Wire November 23, 2021

Oragenics Awarded a $250,000 Grant from the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics.

Business Wire October 4, 2021

Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate

Business Wire September 15, 2021

Oragenics' SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice with Intramuscular and Intranasal Adjuvants

Business Wire August 30, 2021

Oragenics Announces Postponement of Annual Meeting of Shareholders

Business Wire August 24, 2021

Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines

Business Wire July 27, 2021

Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

Business Wire July 1, 2021

Oragenics Issues Letter to Shareholders

Business Wire May 18, 2021

Oragenics Announce Changes in Management and Board of Directors

Business Wire May 3, 2021

Oragenics Enters into Material Transfer Agreement with Biodextris for Mucosal Adjuvant for Intranasal COVID-19 Vaccine

Business Wire March 9, 2021

Oragenics to Participate in Two Investment Conferences During March

Business Wire March 8, 2021

Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling $21.9 Million and the Redemption of Its Series C Preferred Stock

Business Wire February 12, 2021

SARS-CoV-2 Spike Protein Licensed by Oragenics from the NIH Demonstrates Protective Immunity in Mice

Business Wire February 2, 2021

Oragenics Issues Letter to Stockholders

Business Wire January 14, 2021

Oragenics Enters Into Material Transfer Agreement With Adjuvance Technologies for COVID-19 Vaccine Adjuvant

Business Wire January 7, 2021